Liver Surgery for Breast Cancer That Has Spread to the Liver: What the Evidence Really Shows

Table of Contents

• Key Points
• Background: Why This Question Matters
• How This Review Was Conducted
• Why Breast Cancer Liver Metastases Are Treated Differently
• What the Published Reviews Found
• Key Findings: Survival, Risk, and Selection
• Which Factors Predict a Better Outcome?
• The Four Comparison Studies in Detail
• The Cost-Effectiveness Analysis
• Clinical Implications: What This Means for Patients
• Limitations: What This Research Cannot Prove
• Recommendations for Patients and Families
• Frequently Asked Questions
• Source Information

Key Points

• Liver resection for breast cancer that has spread only to the liver remains unproven; no randomized trials exist and the evidence is weak.
• Across studies, five-year survival after surgery ranged from 21% to 58%, and postoperative death rates ranged from 0% to 5%.
• Three of four comparison studies found better survival with surgery than chemotherapy alone, but all were retrospective and had weak designs.
• The only consistent predictor of better outcome is a long interval between treatment of the original breast tumor and diagnosis of liver metastases.
• Chemotherapy remains the standard first-line approach; surgery may be proposed when clear margins are possible while preserving at least 30% of the liver.

Background: Why This Question Matters

Breast cancer (BC) is one of the most common cancers in women. In 2018, the estimated age-adjusted annual incidence across 40 European countries was 145.2 cases per 100,000 women, and the death rate was 32.8 per 100,000 women. Breast cancer remains the leading cause of cancer-related death among European women.

The number of new cases rose after mammography screening was introduced, and it continues to climb as the population ages. At the same time, the death rate has fallen in most Western countries. Better treatments and earlier detection explain much of that improvement.

The main reason breast cancer kills is metastatic spread — cancer that has traveled to other organs. The liver is the third most common site of spread, after the lymph nodes and the lungs. About 30% of patients with breast cancer will develop metastases at some point. Only 5% to 25% of these patients have cancer limited to the liver alone (isolated liver metastases). Those patients are the potential candidates for liver surgery or other liver-directed treatments.

Current guidelines do not recommend routine scanning for distant spread after the primary tumor is treated. Instead, follow-up relies on medical history, physical examination, and regular mammography. These visits occur every 3 to 6 months for the first 3 years, every 6 to 12 months for the next two years, and once a year afterward. Blood counts, chemistry panels, bone scans, chest X-rays, liver ultrasounds, CT scans, PET scans, MRI, and tumor markers are not recommended for routine follow-up in an otherwise healthy patient with no symptoms or exam findings. As a result, doctors usually do not systematically hunt for distant metastases.

Early research shaped this cautious approach. In those first papers, patients whose cancer spread to the bone had a median survival of 48 months, with a strong benefit from the first hormonal therapy given — effective in 87% of patients (median response 10 months). Any type of chemotherapy worked in 93% of those patients (median response 11 months). In contrast, patients whose cancer spread anywhere else had a significantly shorter median survival of just 17 months.

That early finding spread quickly through clinical practice, and its influence lingers today. Metastatic breast cancer came to be viewed as universally "systemic" — meaning it was assumed to be everywhere in the body — so treating one isolated spot in the liver seemed pointless.

A collective series from 8 international centers over 24 years collected only 119 liver resections performed for breast cancer liver metastases. If roughly 10% of women with breast cancer develop metastatic disease confined to the liver, about 96,000 cases would be expected in the United States over that same period. The gap between the theoretical number of candidates and the number of operations actually performed is enormous.

How This Review Was Conducted

This is a narrative review — a structured summary of the existing scientific literature rather than a new experiment. The author collected and analyzed recent papers on hepatectomy (liver removal surgery) for breast cancer liver metastases.

The evidence base included:

• Case series (reports of patients treated at single centers)
• Previously published literature reviews
• Comparative studies (surgery versus other treatments)
• One cost-utility analysis (comparing cost and benefit of treatments)

Studies were selected based on how they addressed surgery, possible prognostic factors (features that predict outcome), and long-term survival. The review was prepared following the Narrative Review reporting checklist.

Why Breast Cancer Liver Metastases Are Treated Differently

Liver metastases from breast cancer are handled very differently from liver metastases that come from colon (colorectal) cancer. This contrast explains much of the confusion in the field.

• Effective chemotherapy: For breast cancer, effective chemotherapy has been established for a long time. For colon cancer, it was established only recently.
• Role of liver surgery: With breast cancer, even when the disease is readily removable, patients almost always receive first-line chemotherapy instead. With colon cancer, surgery is the only truly effective first-line treatment.
• Perception of surgery: Liver surgery is often seen as excessively invasive for breast cancer patients, especially since breast cancer care has steadily moved toward more conservative approaches.

This mindset persists even though specialized liver centers have become much safer. The French report showed that liver resection for breast cancer metastases made up one third of all non-colorectal, non-endocrine liver procedures, with a median survival of 45 months. Survival rates after these operations were comparable to those achieved for all other types of non-colorectal, non-endocrine liver metastases. In a well-known clinical scoring system used to predict survival after hepatectomy, having surgery for breast cancer liver metastases actually carried a "protective" effect.

Despite these encouraging data, there is still no clear proof that surgery improves how long patients live.

What the Published Reviews Found

Between 2006 and 2018, ten major literature reviews appeared. Nine focused on surgical removal; one (Vogl, 2013) covered percutaneous thermal ablation — a technique that destroys tumors with heat rather than removing them surgically.

• Elias (2006, HPB): 9 studies, resection, minimum more than 10 patients
• Howlader (2011, Int J Surg): 11 studies, resection, at least 9 patients
• Chua (2011, Eur J Cancer): 19 studies, resection, more than 10 patients
• Vogl (2013, Eur Radiol): 8 studies, thermal ablation
• Vertriest (2015, Dig Surg): 17 studies, resection
• Fairhurst (2016, Breast): 33 studies, resection, more than 5 patients
• Golse (2017, Clin Breast Cancer): 18 studies, principal series published since 2000
• Yoo (2017, Breast): 43 studies, resection
• Ercolani (2018, Dig Surg): 10 studies, resection, more than 40 patients
• Tasleem (2018, Ir J Med Sci): 25 studies, resection

Selection criteria varied from review to review. The number of studies included in any single review ranged from 8 to 43. Only one review required series with more than 40 cases, which narrowed the field to just 10 series. Two reviews set a minimum of 10 cases. One review simply took "principal series published since 2000," capturing 18 papers.

Key Findings: Survival, Risk, and Selection

The most striking feature of the evidence is how inconsistent it is. Reported postoperative mortality (death within the period right after surgery) ranged from 0% to 5%. Reported 5-year overall survival ranged from 21% to 58%. That enormous spread raises serious questions about which patients were chosen for surgery in each study.

The largest review took into account 43 papers that met defined search criteria, chosen from a pool of 1,705 potentially relevant citations. Its reported 30-day mortality rate was 0.7% — 6 deaths among the 918 patients for whom this information was available. Median overall survival was 56% at 3 years and 37% at 5 years.

Yet the quality of reporting was poor:

• Only 21 of 43 studies (48.8%) described any selection criteria for surgery.
• Only 6 studies (14.0%) included more than 50 patients.
• Only 22 of 43 papers (51.2%) investigated possible prognostic factors.
• Even a basic variable like "age" was reported in only 15 of those 22 studies (68.2%).

Among the studies that examined age, 12 found no influence on long-term results. Two studies reported better results in patients over 50 years old, and one study found better survival in patients younger than 50. These contradictory results show how unreliable individual prognostic factors have been.

Study periods also tended to be very long, because so few operations are performed for this indication. Centers had to collect cases over many years to reach a meaningful number. Long study periods introduce bias in selection, staging, and surgical technique, since standards changed over time.

Which Factors Predict a Better Outcome?

Only one factor consistently showed a positive influence on survival: a prolonged interval between treatment of the primary breast cancer and the diagnosis of liver metastases. In plain terms, the longer the gap between the original breast cancer treatment and the discovery of liver spread, the better the outlook.

A separate single-center report described 162 hepatectomies performed in 139 consecutive women. That study identified factors linked to worse survival:

• More than one liver metastasis
• "Triple negative" disease (negative receptor status for estrogen, progesterone, and HER2/Neu receptors)
• Microscopic vascular invasion (cancer cells seen inside small blood vessels)

The same study identified factors linked to better long-term survival:

• Negative resection margins (no cancer cells at the cut edge of the removed tissue)
• Hormonal therapy given both before and after liver resection
• Repeated hepatectomy (a second operation if cancer returns)

This was the only paper offering a nomogram — a visual tool that estimates 3-year and 5-year survival after hepatectomy. The author notes it would be far more useful to predict outcomes before surgery than after.

Other analyses found that an ER-negative primary tumor (estrogen-receptor negative) and disease progression before surgery were both linked to poor outcomes after liver resection. In contrast, among patients with ER-positive tumors whose disease was stable or responding to systemic therapy, surgery was strongly associated with improved survival compared with chemotherapy alone.

The Four Comparison Studies in Detail

Comparative studies provide the strongest evidence about whether a treatment works. All four available studies are retrospective (looking backward at existing records) and all have weak designs. Detailed findings follow.

The French Study (2013)

This study evaluated 51 medically treated patients against 49 surgically treated patients, drawn from 100 patients treated with surgery. Groups were matched for age at breast cancer diagnosis. Groups were matched for year of breast cancer diagnosis. Groups were matched for time between diagnosis and first liver metastasis. Groups were matched for TNM stage of the original breast cancer. Groups were matched for hormone receptor status. Groups were matched for ductal or lobular histology.

Surgery was offered when: (I) liver metastases were resectable (4 or fewer); (II) disease was stable or responding to chemotherapy and/or hormone therapy; (III) performance status was 0 to 1. Bone metastases were permitted only if they did not grow during treatment.

The surgically treated group had significantly better survival. Across the whole cohort of 100 patients, better survival was predicted by negative lymph node status of the primary tumor. Better survival was predicted by receiving a single course of chemotherapy. Better survival was predicted by no bone metastases at the time of liver spread. Better survival was predicted by undergoing liver surgery.

The Second 2013 Study

This study compared 38 patients treated with chemotherapy over 7 years against 26 patients with isolated liver metastases who received liver-directed therapies. Twelve had liver resections when disease was confined to one lobe, regardless of the number of lesions. Fourteen had percutaneous radiofrequency ablation (a needle-based heat treatment) because the metastases were in both lobes and no lesion exceeded 6 centimeters.

Treated patients lived longer than the control group: median survival 21.1 months versus 9.7 months. Patients treated with resection did better than those treated with local ablation.

The Propensity Score Study (2016)

This study included 167 patients out of 2,150 evaluated by a multidisciplinary tumor board over 23 years. The surgical cohort had 69 patients (41%), and the medical cohort had 98 patients (59%). A propensity score analysis (a statistical method that balances groups for differences in patient characteristics) was used to control for selection bias.

This study did not show any survival benefit from liver-directed therapies compared with medical therapy alone. However, the authors did claim that surgery gave patients at least a temporary disease-free period, allowing them to stop toxic therapy for a while.

The UK Tertiary Center Study (2017)

This report described 61 patients with isolated liver metastases treated with surgery (23 patients), percutaneous radiofrequency ablation (11 patients), or chemotherapy alone (27 patients). Surgery or ablation was proposed when disease was resectable at first evaluation, or when disease responded to systemic chemotherapy and then became resectable. Better survival was reported for patients who had surgery or ablation. The presence of extrahepatic disease (cancer outside the liver) considerably reduced survival after any treatment.

Overall, three of the four comparison studies reported better results with liver resection or thermal ablation than with chemotherapy alone. Surprisingly, when surgical indications were described, having multiple nodules did not rule out surgery. One study operated with 4 or fewer metastases; another operated when metastases were confined to one lobe, regardless of how many there were.

The Cost-Effectiveness Analysis

Only one cost-utility analysis (a study comparing both cost and health benefit) has been published. It examined two scenarios using three strategies. In both scenarios, Strategy A was liver resection followed by conventional systemic therapy.

• First scenario: Strategy A compared with conventional systemic chemotherapy alone (Strategy B)
• Second scenario: Strategy A compared with a newer systemic therapy alone (Strategy C)

For patients with ER-positive tumors, liver resection plus systemic therapy was more cost-effective than systemic therapy alone. For patients with HER2-positive tumors, hepatectomy plus systemic chemotherapy had cost-effectiveness comparable to systemic therapy alone.

Additionally, liver resection plus standard systemic chemotherapy was more cost-effective than giving newer systemic chemotherapy agents. Altogether, 2 of the 3 scenarios favored treatment with surgery followed by conventional chemotherapy.

Clinical Implications: What This Means for Patients

Liver resection for breast cancer liver metastases remains an unresolved question for liver surgeons. Most published papers are single-center reports, and their conclusions are confounding rather than clarifying. The author states plainly that there are no strong lines of evidence supporting the inclusion of surgical therapy within the recommended treatments for breast cancer liver metastases.

Current guidelines state that the first approach for metastatic disease is systemic chemotherapy — and that is what happens in practice today. There is no scientific literature supporting any particular feature of liver metastases as a reliable criterion for deciding who should have surgery.

The heterogeneity across studies is severe. Clinical variables, number of patients, observation time, and reporting methods all differ. This makes it impossible to give clear advice about who should or should not be operated on. The author even questions whether continuing to publish such papers is worthwhile.

Still, a few practical conclusions have emerged. First, surgery for breast cancer liver metastases appears feasible and safe in experienced hands. Second, a small number of patients clearly do well after surgery. Third, the biggest uncertainty is not whether the operation can be done — it is whether it truly extends life compared with modern chemotherapy.

Limitations: What This Research Cannot Prove

The evidence suffers from fundamental weaknesses that patients and families should understand:

1. No randomized trials exist. No study randomly assigned patients to surgery or chemotherapy, so no study can prove cause and effect.
2. All comparison studies are retrospective. They look backward at records, which allows selection bias to influence results.
3. Only one study reported the inclusion criteria for the medical (control) group. Without that, comparing groups fairly is difficult.
4. Only one paper studied liver resection alone. The others combined resection with percutaneous ablation, muddying which treatment produced the benefit.
5. Only two papers described their criteria for surgery. Three obtained their data from multidisciplinary tumor board meetings, which introduces its own selection patterns.
6. Study periods were extremely long because so few procedures are performed — up to 24 years in one series. Standards for imaging, staging, chemotherapy, and surgery all changed during those periods.
7. Reporting is inconsistent. Even age was missing from a third of the prognostic analyses.

Another limitation concerns the way scientific strength was assessed. The comparative studies were weakly designed. Their statistical techniques varied. One used a case-control approach. One used a propensity score analysis. Two simply analyzed survival without cross-citing each other's work.

Recommendations for Patients and Families

Based on this review, the following guidance emerges for patients with breast cancer that has spread to the liver:

1. Understand that chemotherapy remains the standard first-line approach. This reflects current guidelines and everyday practice.
2. Surgery can reasonably be proposed when it is possible to perform radical surgery with R0 margins (no cancer cells at the cut edge) while preserving at least 30% of the liver along with its vascular and biliary connections.
3. Stable bone metastases are not a contraindication. Patients with bone lesions that are not growing may still be candidates for liver surgery.
4. The interval between treatment of the primary breast cancer and the diagnosis of liver metastases is the only prognostic criterion available. A longer interval generally suggests a better outlook.
5. Ask your care team about multidisciplinary review. Three of the four comparative studies drew their data from multidisciplinary tumor board meetings, where surgeons, oncologists, and radiologists review cases together.
6. Discussions about surgery are best framed honestly: the operation can be done safely in experienced centers, but no definitive proof shows it extends survival compared with chemotherapy alone.

The takeaway is not that surgery is useless — it is that the evidence is not yet strong enough to settle the debate. Patients considering liver-directed treatment should weigh the genuine uncertainty alongside their own circumstances, preferences, and the expertise of their treatment center.

Frequently Asked Questions

What is liver resection for breast cancer that has spread to the liver?

Liver resection is surgery to remove part of the liver. It is considered for breast cancer that has spread only to the liver, called isolated liver metastases. Only 5% to 25% of patients with metastatic breast cancer have cancer limited to the liver alone, making them potential candidates for this operation or other liver-directed treatments.

Does liver resection for breast cancer liver metastases extend life?

It remains unproven. No randomized trials exist, and the evidence is weak. Three of four comparison studies found better survival with surgery than chemotherapy alone, but all were retrospective. The author concludes there is still no definitive proof that liver surgery extends life for these patients compared with modern chemotherapy.

What are the risks of liver resection for breast cancer liver metastases?

Reported postoperative death rates ranged from 0% to 5% across studies. This wide range suggests different hospitals operate on very different types of patients. The operation appears feasible and safe in experienced hands, but the main uncertainty is whether it truly extends life compared with chemotherapy alone.

Who might be considered for liver surgery for breast cancer liver metastases?

Surgery may be proposed when radical removal with clear margins is possible while preserving at least 30% of the liver along with its vascular and biliary connections. Stable bone metastases are not a contraindication. The only consistent predictor of better outcome is a long gap between treating the original breast tumor and finding liver metastases.

What does a five-year survival of 21% to 58% after liver resection mean?

It means that across studies, between 21 and 58 out of every 100 patients were still alive five years after surgery. This wide range reflects differences in which patients were selected for surgery in each study, not a single reliable estimate for any individual patient.

What is the standard first-line treatment for breast cancer that has spread to the liver?

Chemotherapy remains the standard first-line approach. Current guidelines state that the first treatment for metastatic disease is systemic chemotherapy, and this is what happens in practice today. Surgery is not routinely recommended because there is no strong evidence supporting its inclusion in standard treatment for breast cancer liver metastases.

What should patients and families discuss with the care team about liver surgery?

Ask about multidisciplinary review, where surgeons, oncologists, and radiologists discuss cases together. Frame the discussion honestly: the operation can be done safely in experienced centers, but no definitive proof shows it extends survival compared with chemotherapy alone. Weigh the genuine uncertainty alongside your own circumstances, preferences, and the expertise of your treatment center.

When should a patient with breast cancer that has spread only to the liver seek a second opinion about liver surgery?

Because no randomized trials exist and comparison studies are retrospective, the evidence cannot settle whether liver surgery extends life compared with chemotherapy alone. Five-year survival after surgery ranged from 21% to 58%, and postoperative death rates from 0% to 5%, suggesting centers operate on very different patients. A second opinion is reasonable when surgery is proposed. Criteria for selecting patients vary. Only one factor consistently predicts a better outcome. That factor is a long interval between the original breast cancer treatment and the liver diagnosis. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Renewed considerations on the utility (or the futility) of hepatic resections for breast cancer liver metastases

Author: Gian Luca Grazi, Hepatobiliary Biliary Pancreatic Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Article type: Review Article

Publication: HepatoBiliary Surgery and Nutrition, 2021;10(1):49-58. doi: 10.21037/hbsn.2019.07.12. Submitted April 13, 2019; accepted July 12, 2019.

This patient-friendly article is based on peer-reviewed research. It summarizes a review of previously published studies and does not present new experimental data. Patients should discuss all treatment decisions with their own medical team.